[go: up one dir, main page]

SE9903021D0 - Reduction of the immunogenicity of non-human grafts - Google Patents

Reduction of the immunogenicity of non-human grafts

Info

Publication number
SE9903021D0
SE9903021D0 SE9903021A SE9903021A SE9903021D0 SE 9903021 D0 SE9903021 D0 SE 9903021D0 SE 9903021 A SE9903021 A SE 9903021A SE 9903021 A SE9903021 A SE 9903021A SE 9903021 D0 SE9903021 D0 SE 9903021D0
Authority
SE
Sweden
Prior art keywords
relates
tissue
removal
porcine
macrophages
Prior art date
Application number
SE9903021A
Other languages
Swedish (sv)
Inventor
Thomas Brevig
Tom Kristensen
Jan Holgersson
Rasmussen Jens Zimmer
Original Assignee
Absorber Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Absorber Ab filed Critical Absorber Ab
Priority to SE9903021A priority Critical patent/SE9903021D0/en
Publication of SE9903021D0 publication Critical patent/SE9903021D0/en
Priority to PCT/SE2000/001648 priority patent/WO2001013947A1/en
Priority to AU70460/00A priority patent/AU774651B2/en
Priority to JP2001518083A priority patent/JP2003507131A/en
Priority to EP00959076A priority patent/EP1207903A1/en

Links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to a transplantion material produced by dissociation of porcine tissue and removal of macrophages and/or microglial cells therefrom. The tissue could be an embryonic or fetal neural tissue and the removal could be effected by exposing the preparation above to antibodies against the Gal alpha 1-3Gal beta 1-R epitope and a complement reagent. The invention also relates to the use of such a transplantation material for preparing a pharmaceutical preparation useful when transplanting neural tissue. The invention also relates to a kit comprising one or more enzymes for tissue dissociation, an antibody preparation and a complement reagent. The invention also relates to a process for removal of macrophages and/or microglial cells from porcine embryonic or fetal neural tissue. Finally, the invention relates to a process for treatment of neurological disorders with such pretreated porcine neural grafts.
SE9903021A 1999-08-26 1999-08-26 Reduction of the immunogenicity of non-human grafts SE9903021D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SE9903021A SE9903021D0 (en) 1999-08-26 1999-08-26 Reduction of the immunogenicity of non-human grafts
PCT/SE2000/001648 WO2001013947A1 (en) 1999-08-26 2000-08-28 Reduction of the immunogenicity of non-human grafts
AU70460/00A AU774651B2 (en) 1999-08-26 2000-08-28 Reduction of the immunogenicity of non-human grafts
JP2001518083A JP2003507131A (en) 1999-08-26 2000-08-28 Reduced immunogenicity of non-human grafts
EP00959076A EP1207903A1 (en) 1999-08-26 2000-08-28 Reduction of the immunogenicity of non-human grafts

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9903021A SE9903021D0 (en) 1999-08-26 1999-08-26 Reduction of the immunogenicity of non-human grafts

Publications (1)

Publication Number Publication Date
SE9903021D0 true SE9903021D0 (en) 1999-08-26

Family

ID=20416763

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9903021A SE9903021D0 (en) 1999-08-26 1999-08-26 Reduction of the immunogenicity of non-human grafts

Country Status (5)

Country Link
EP (1) EP1207903A1 (en)
JP (1) JP2003507131A (en)
AU (1) AU774651B2 (en)
SE (1) SE9903021D0 (en)
WO (1) WO2001013947A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060147429A1 (en) * 2004-12-30 2006-07-06 Paul Diamond Facilitated cellular reconstitution of organs and tissues
EP3401682A1 (en) * 2017-05-09 2018-11-14 Université de Nantes Diagnosis, prevention and treatment of demyelinating disorders of the central nervous system
CN109187958A (en) * 2018-09-12 2019-01-11 福建中医药大学附属人民医院（福建省人民医院） A kind of rat CD4 antibody coating magnetic bead and its preparation method and application and the kit containing the magnetic bead

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2221234A1 (en) * 1995-05-15 1996-11-21 Cedars-Sinai Medical Center Compositions and methods for inhibiting xenograft rejection
US6610288B1 (en) * 1995-05-26 2003-08-26 Diacrin, Inc. Porcine hepatocytes for use in treatment of disorders characterized by insufficient liver function

Also Published As

Publication number Publication date
EP1207903A1 (en) 2002-05-29
AU7046000A (en) 2001-03-19
WO2001013947A1 (en) 2001-03-01
AU774651B2 (en) 2004-07-01
JP2003507131A (en) 2003-02-25

Similar Documents

Publication Publication Date Title
ATE202688T1 (en) IN VITRO PRODUCTION OF A CORNEA EQUIVALENT MODEL
ES2059537T3 (en) METHOD FOR PURGING IN VITRO RESIDUAL TUMOR CELLS WITH THE AID OF CYTOTOXIC CELLS ACTIVATED BY A LYMPHOCINE.
AU2369595A (en) In vitro growth of functional islets of langerhans and in vivo uses thereof
ATE553766T1 (en) PREPARATION AND XENOTRANSPLANTATION OF ISLANDS OF LANGERHANS FROM PIGS
CA2263729A1 (en) Process for producing mammals with defined genetic properties
DK0759032T3 (en) Isolated peptides derived from MAGE-3 and complexing with HLA-A2 molecules and their use
DE60040134D1 (en)
WO2001068814A3 (en) Multipotent cell and cardiomyocyte cell populations, and routes to and uses of same
FI894001A0 (en) VAEXTGUMMIMATERIAL OCH DESS ANVAENDNING I LIVSMEDELSPRODUKTER.
HUT47601A (en) Process for releasing cell-mixtures and tissues from non-desirable population
SE9903021D0 (en) Reduction of the immunogenicity of non-human grafts
DE69004011D1 (en) Process for the preparation of overbased sulfurized alkaline earth phenolates of the detergent type.
IL147123A0 (en) Compositions containing soluble forms of hla-g for treating inflammatory skin pathologies
Muramatsu Embryoglycan: a highly branched poly-N-acetyllactosamine in pluripotent stem cells and early embryonic cells
IL93024A0 (en) Introduction of exogenous dna into somatic and germ animal cells
WO2003033685A3 (en) Method of producing human beta cell lines
AU7913887A (en) Method for the removal of undesired cells from human lymphocyte populations, application of the method in monoclonal antibody production and kit therefor
EP0292719A3 (en) A test for rhizoctonia brown and yellow patch
AU3018289A (en) Anaplasma marginale antigen, antigen compositions, vaccine and process for the production of said antigen, antigen compositions, and vaccine
EP0380084A3 (en) Method for the inhibition of cell-cell and cell substratum interactions by the blocking of carbohydrate-carbohydrate interactions
IE880729L (en) A process for the isolation of basement membrane proteins¹from human and animal tissues
ATE43610T1 (en) ACINO-FOETAL DIFFERENTIATION PROTEINS ASSOCIATED WITH PANCREAS CANCER, ANTISERUM AND MONOCLONAL ANTIBODIES TO THESE PROTEINS AND METHODS FOR THEIR PRODUCTION.
AU3189199A (en) Antisense modulation of lfa-3
ATE58397T1 (en) MONOCLONAL ANTIBODIES SUITABLE FOR SPECIFIC DIFFERENTIATION OF HUMAN HEPATOCARCINOMA CELLS.
DE69920216D1 (en) BIOLOGICAL MATERIAL FOR THE PRODUCTION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MAMMALS